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Abstract
Recently, two large genome wide association studies, conducted in Chinese populations, reported
associations between upper gastrointestinal (GI) cancer and the rs2274223, rs13042395 and
rs4072037 polymorphisms in PLCE1, C20orf54 and MUC1 respectively. We set out to determine
whether similar associations existed for Caucasian populations.
We genotyped two population-based, case-control studies of upper GI cancer; the first included
290 gastric cancer cases and 376 controls; the second study included 306 gastric cancer cases, 107
oesophageal adenocarcinoma cancer cases, 52 oesphageal squamous cell cancer cases, and 211
controls. Odds ratios (OR) and 95% confidence intervals (CI) were computed from logistic models
and adjusted for confounding variables.
The rs4072037 polymorphism in MUC1 was associated with a reduced risk of gastric cancer of
intestinal histological type (OR 0.4; 95% CI 0.2–0.9), and a reduced risk of oesophageal squamous
cell cancer (OR 0.5; 95% CI 0.2–1.0), but not oesphageal adenocarcinoma. Likewise, rs2274223
in PLCE1 was associated with a reduced risk of oesophageal squamous cell cancer (OR 0.5; 95%
CI 0.3–1.0) but not oesphageal adenocarcinoma. We observed no association between rs13042395
in Corf54 and risk of gastric or oesphageal cancer in either of the two studies.
Our findings for rs4072037 and gastric cancer risk are in keeping with one previous report for a
Caucasian population. To the best of our knowledge this is the first study to report an association
between rs2274223 and rs4072037 and risk of oesophageal squamous cell carcinoma in a
Caucasian population.
Introduction
We have witnessed great advances in our understanding of the genetic basis of gastric and
oesphageal cancers (upper gastrointesinal (GI) cancers). This has been the result of well-
powered, genome wide association studies (GWAS) exploring the relationship between a
large number of single nucleotide polymorphisms (SNP) and disease predisposition.
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Recently, two large GWAS, conducted in Chinese populations, reported associations
between gastric cancer (GC) and oesphageal squamous cell carcinoma (OSCC), and a
number of previously unknown disease-susceptibility loci at 1q22, 10q23 and 20p13 (Abnet,
Freedman et al. 2010, Wang, Zhou et al. 2010). Of particular interest were three SNP:
rs2274223 (G>A) in PLCE1 at 10q23 and rs13042395 (T>C) in C20orf54 at 20p13, which
were shown to increase risk for GC and OSCC, and rs4072037 (G>A) in MUC1 at 1q22,
which was shown to confer protection from GC. We set out to determine whether similar
associations existed for Caucasian populations.
Materials and methods
Study groups
We genotyped two, Caucasian, population-based, case-control studies of upper GI cancer:
the first included 290 GC cases (predominantly non-cardia GC) and 376 controls derived
from a population in Warsaw, Poland (Chow, Swanson et al. 1999); the second study,
derived from three distinct geographical areas of the United states holding population based
cancer registries, included 122 cardia GC cases, 184 non-cardia GC cases, 107 oesophageal
adenocarcinoma cancer cases (OACC), 52 OSCC), and 211 controls (Gammon, Ahsan et al.
1997).
Genotyping
DNA samples were genotyped by real-time PCR allelic discrimination using the ABI
7900HT Fast Sequence Detection System (Applied Biosystems, Foster City, CA).
Predesigned TaqMan SNP genotyping assays were employed, utilizing minor groove
binding probes 5′-labeled with VIC or FAM fluorophores to detect the allelic variants in
rs2274223, rs13042395, rs4072037 (Applied Biosystems). Following analysis of real time
data, genotyping calls were possible in 98% of samples for the rs13042395 and rs4072037
SNPs and >96% for rs2274223SNP.
Statistics
Hardy–Weinberg equilibrium (HWE) of alleles was assessed at the polymorphic loci by χ2
statistics. Odds ratios (OR) with Cornfield 95% confidence intervals (CIs) were computed
by logistic regression, and adjusted for age and sex using STATA software (version 7.0;
STATA Press, College Station, TX).
Results
For all three SNP, the distribution of alleles was in HWE, with non-significant χ2 values in
both control groups.
The rs4072037 polymorphism (G>A) in MUC1 was inversely associated with risk of
intestinal GC, and OSCC, in the US study group. For intestinal type GC, the association was
observed for heterozygotes, with an OR of 0.4 (95% CI 0.2–0.9), and in a dominant model
(OR 0.4 (95% CI 0.2–0.9)). Similarly for OSCC, the association was observed for
heterozygotes (OR 0.4 (95% CI 0.2–0.9)) and in dominant model (OR 0.5 (95% CI 0.2–
1.0)).
The rs2274223 polymorphism (G>A) in PLCE1 was inversely associated with risk of OSCC
in the US study group. The association was significant only in heterozygotes (OR 0.5; 95%
CI 0.2–1.0) (see table 2). No associations were observed between the rs2274223
polymorphism and GC in either the Polish or US study groups.
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No associations were observed between the rs13042395 polymorphism in C20orf54 and risk
upper GI cancer in either study population (results not shown).
Discussion
The rs2274223 polymorphism in PLCE1 was identified as a risk factor for GC and OSCC in
Han Chinese populations by two contemporaneous independent GWAS (Abnet, Freedman et
al. 2010, Wang, Zhou et al. 2010).
The association with GC was subsequently reproduced in another study in Han Chinese
(Zhang, Jin et al. 2011). In Caucasian populations, associations have been reported between
rs2274223 and risk for non-oropharyngeal squamous cell carcinoma of the head and neck
(Ma, Wang et al. 2011). Our finding of an association with OSCC is in the opposite
direction to those reported in the literature; such affects themselves are not, however, novel,
with opposing effects observed for other SNPs reported for different tumour sites
(Lochhead, Frank et al. ). Interestingly, the results of a study in a Chinese population suggest
that rs2274223 confers a survival advantage in GC (Luo, Gao et al. 2011).
PLCE1 encodes an enzyme that catalyses the hydrolysis of phosphatidylinositol-4,5-
bisphosphate, generating the secondary messengers inositol 1,4,5-triphosphate and
diacylglycerol, which participate in cell growth, differentiation and gene expression
(Bunney, Baxenale et al. 2009). PLCE1 is regulated by small GTPases of the Ras, Rap and
Rho families, and contains a guanine nucleotide exchange factor domain for Ras-like small
GTPases at its N-terminus, and two Ras-binding domains at its C-terminus (Bunney,
Baxenale et al. 2009, Kelley, Reks et al. 2001, Wing, Bourdon et al. 2003). The latter two
domains bind directly to H-ras (Kelley, Recks et al. 2001). PLCE1 also interacts with IQ-
domain GTPase-activating protein 1 (IQGAP1) (Hinkes, Wiggins et al. 2006). IQGAP1 has
important roles in angiogenesis, and is expressed in endothelial cells where it binds
VEGFR2, an important factor for endothelial cell rearrangement and migration (Johnson,
Sharma et al. 2009).
With little known about rs2274223 prior to the aforementioned GWAS, no functional data
exist. In colorectal cancer (CRC), PLCE1 expression is significantly down-regulated
compared to the normal colonic mucosa, with increasing suppression of PLCE1 correlated
with advancing tumour stage (Danielsen, Cekaite et al. 2011). In a CRC cell line,
overexpression of PLCE1 was found to inhibit cell proliferation and promote apoptosis
(Wang, Zhou et al. 2011). These findings suggest that PLCE1 functions as a tumour
suppressor gene; however, tumour promoting effects for PLCE1 have also been reported. In
the APC min/+ mouse, knockout of PLCE1 was associated with resistance to tumour
development through attenuation of angiogenesis and tumour associated inflammation (Li,
Edamatsu et al. 2009). Similar pro-inflammatory actions have been observed in skin
carcinogenesis (Bai, Edamatsu et al. 2004).
The finding that rs4072037 in MUC1 protects against GC has been validated in Han Chinese
(Zhang, Jin et al. 2011, Shi, Hu et al. 2011), Japanese, South Korean (Saeki, Saito et al.
2011), and Caucasian populations (Jia, Persson et al. 2010).
The mucin, MUC1, is a highly glycosylated trans-membrane glycoprotein that is a major
component of the viscous mucous layer protecting epithelial surfaces. Functional studies
have shown that rs4072037, in the MUC1 gene, regulates alternative splicing of the second
exon, and modifies the transcriptional activity of the promoter (Saeki, Saito et al. 2011).
However, the mechanism by which rs4072037 contributes to GC development has yet to be
elucidated.
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More recently, it has been shown that MUC1 participates intracellularly in the activation of
the NF-κB, leading to up-regulation of cytokines IL-6 and TNF-α (Cascio, Zhang et al.
2011). This is an interesting and novel observation, given that prognosis in both GC and
OSCC is inversely associated with MUC1 expression (Utsunomiya, Yonezawa et al. 1998,
Ye, Yan et al. 2011). Moreover, MUC1 expression in OSCC upregulates the expression of
matrix metalloproteinase 13, a protein which is highly expressed in tumours of patients with
metastatic OSCC, and which is indirectly regulated by NF-κB through the production of
pro-inflammatory cytokines (Ye, Yan et al. 2011). As such, this provides a potential
mechanism by which tumours can promote inflammation and tumour development through
MUC1 expression.
Despite being a risk factor for upper GI cancer in Asians, our data do not support a role for
rs13042395 and upper GI cancer risk in Caucasians. However, as the minor allele is at such
a low frequency in our study populations, we cannot exclude the possibility that we were
unable to detect an association due to lack of power.
rs2274223 has been reported by others to be in linkage disequilibrium (LD) with NOC3L
and another SNP in PLCE1, rs3203713, (Zhang, Jin et al. 2011). In addition, rs4072037 has
been reported to be in LD with the small allele of the variable number of tandem repeats in
the second intron of MUC1 (Jia, Persson et al. 2010). With no functional data, it is possible
that the associations we observed are due to linkage with these or another functional
polymorphism in the same region.
The fact that our observed associations were most apparent in heterozygotes is worth some
consideration. While this could be due to a heterozygote advantage, it is likely that these
findings reflect power limitations by small number of homozygote minor allele cases in the
study groups. Indeed, in support of this explanation, our dominant models are in accordance
with the observed associations for heterozygotes.
Given that we considered this an exploratory study, we have not corrected for multiple
comparisons, and cannot exclude the possibility that the significant findings have arisen by
chance. Furthermore, the small number of OSCC cases in the US study results in large
confidence intervals for these ORs. However, we believe that the novelty and potential
importance of our findings merits their validation in additional Caucasian studies of upper
GI malignancy.
In conclusion, this study has added to our knowledge of the complex genetic interactions
that define upper GI cancer risk in Caucasians. These findings may give insight into the
molecular pathogenesis of upper GI malignancy and, in the future, may contribute to
individual risk stratification for prevention and screening.
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